Efficacy and Safety of IDH Inhibitors in AML

Efficacy and safety of FDA-approved IDH inhibitors in the treatment ...

IDH inhibitor is a promising treatment for R/R AML patients with IDH mutations. For patients with newly diagnosed IDH-mutated AML, ...

Efficacy and Safety of IDH Inhibitors in AML: A Systematic Review of ...

In this systematic review, we assessed the efficacy and safety of IDH 1 and 2 inhibitors used alone or in combination with other drugs in IDH 1 and 2 mutated ...

Efficacy and safety of FDA-approved IDH inhibitors in the treatment ...

IDH inhibitor is a promising treatment for R/R AML patients with IDH mutations. For patients with newly diagnosed IDH-mutated AML, IDH inhibitors may not be ...

Efficacy and safety of IDH inhibitors in IDH-mutated cancers

The overall efficacy of IDH inhibitors in treating cancers with IDH mutations is superior to that of conventional medical therapy, potentially ...

Efficacy and safety of IDH Inhibitors in AML: A systematic review of ...

Despite improving treatment for hematological malignancies, advanced acute myeloid leukemia is associated with a poor prognosis. In this ...

Efficacy and tolerability of isocitrate dehydrogenase inhibitors in ...

Highlights · IDH inhibitors were well tolerated by AML patients. · Ivosidenib significantly improved response rates and survival. · Enasidenib significantly ...

Management of isocitrate dehydrogenase 1/2 mutated acute ...

The primary function of the three IDH inhibitors approved for treatment of AML with mutant IDH is to limit the production of 2-HG and induce ...

(PDF) Efficacy and safety of FDA-approved IDH inhibitors in the ...

Conclusion IDH inhibitor is a promising treatment for R/R AML patients with IDH mutations. For patients with newly diagnosed IDH-mutated AML, ...

FEvIR Citation - 37434249 Efficacy and safety of FDA-approved IDH ...

For patients with newly diagnosed IDH-mutated AML, IDH inhibitors may not be optimal therapeutic agents due to low CR rates. The safety of IDH inhibitors is ...

Efficacy and safety of FDA-approved IDH inhibitors in the treatment ...

For patients with newly diagnosed IDH-mutated AML, IDH inhibitors may not be optimal therapeutic agents due to low CR rates and the safety of IDH inhibitors ...

Acute myeloid leukemia with IDH1 and IDH2 mutations - Nature

Enasidenib (IDHIFA, formerly AG-221) is the first-in-class, selective and orally available mutant IDH2 inhibitor which demonstrated efficacy ...

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia

IDH inhibitor monotherapy for R/R AML is efficacious and safe; however, there are problems, such as primary or acquired resistance. Clinical ...

(PDF) Efficacy and safety of IDH inhibitors in IDH-mutated cancers

Conclusion The overall efficacy of IDH inhibitors in treating cancers with IDH mutations is superior to that of conventional medical therapy, ...

Clinical Implications of Isocitrate Dehydrogenase Mutations ... - MDPI

Recently, the Food and Drug Administration approved three mutant IDH (mIDH) inhibitors for the treatment of AML. However, the use of mIDH inhibitors in ...

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia - Frontiers

Phase I/II trials have shown evidence of safety, tolerability, and encouraging evidence of efficacy of two small molecule inhibitors targeting ...

Full article: Efficacy and Safety Profile of Ivosidenib in the ...

Ivosidenib, a potent selective inhibitor of mutant IDH1, is a differentiating agent shown to be clinically effective in newly diagnosed AML (ND-AML) and ...

Concurrent inhibition of IDH and methyltransferase maximizes ...

This compound is currently undergoing safety/efficacy testing in phase I dose escalation trials in patients with relapsed IDH1 mutant AML ( ...

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia

IDH inhibitors as monotherapy ... The IDH1 inhibitor ivosidenib and the IDH2 inhibitor enasidenib were both evaluated in patients with advanced hematological ...

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

This global, double-blind, randomized, placebo-controlled, phase 3 trial assessed the efficacy and safety of ivosidenib and azacitidine as ...

Efficacy and Safety of IDH Inhibitors in AML: A Systematic Review of ...

Efficacy and Safety of IDH Inhibitors in AML: A Systematic Review of Clinical Trials ; Muhammad Ashar Ali ·, ; Shadma Fatima ·, ; Ashish Nepal ·,.